Sushrut Kulkarni - 18 Dec 2025 Form 3 Insider Report for DR REDDYS LABORATORIES LTD (RDY)

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
01 Apr 2026, 11:27:08 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ SUSHRUT KULKARNI

Key filing fact

Sushrut Kulkarni filed Form 3 for DR REDDYS LABORATORIES LTD (RDY) on 01 Apr 2026.

Key facts

  • This page summarizes Sushrut Kulkarni's Form 3 filing for DR REDDYS LABORATORIES LTD (RDY).
  • 0 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 01 Apr 2026, 11:27.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002125150 Primary reporting owner

KULKARNI SUSHRUT

Relationship
GLOBAL HEAD - IPDO
Address
F NO. H-903, APARNA SERENE PARK,, SURVEY NO 146, KONDAPUR, HYDERABAD, INDIA
Signature
/s/ SUSHRUT KULKARNI
Signature date
01 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RDY holding

Equity Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
70
Date
18 Dec 2025
Ownership
Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .